首页 › 三阴性乳腺癌 › 宾夕法尼亚州 › Philadelphia
Philadelphia PA 三阴性乳腺癌临床试验
13项针对 三阴性乳腺癌的研究正在 Philadelphia及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
Study of AVZO-021 in Patients With Advanced Solid Tumors
招募中1/2 期
- Avenzo Therapeutics Recruiting Site, Philadelphia
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
招募中3 期
- Sidney Kimmel Cancer Center at Jefferson ( Site 0049), Philadelphia
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
招募中2 期
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
招募中3 期
- University of Pennsylvania Abramson Cancer Center, Philadelphia
- Lankenau Medical Center, Wynnewood · 距离 7 英里
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
招募中1 期
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
招募中2/3 期
- Abramson Cancer Center of The University of Pennsylvania, Philadelphia
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
招募中2 期
- University of Pennsylvania (U Penn), Philadelphia
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
招募中2 期
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
招募中2 期
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
招募中
- Thomas Jefferson University Hospital, Philadelphia
Role of the Immune Environment in Response to Therapy in Breast Cancer
招募中观察性研究
- Abramson Cancer Center, Philadelphia
其他城市的 三阴性乳腺癌试验
- Houston, TX42 项研究
- New York City, NY31 项研究
- Nashville, TN28 项研究
- Los Angeles, CA27 项研究
- Boston, MA26 项研究
- San Antonio, TX23 项研究
- St. Louis, MO21 项研究
- Arlington, VA20 项研究
- Atlanta, GA20 项研究
- Dallas, TX18 项研究
- Chicago, IL16 项研究
- Columbus, OH16 项研究
Philadelphia的其他研究
- 癌症（所有类型）59 项研究
- 乳腺癌56 项研究
- 非小细胞肺癌51 项研究
- 转移性癌症46 项研究
- 前列腺癌44 项研究
- 结直肠癌44 项研究
- 卵巢癌44 项研究
- 肺癌36 项研究
- 急性髓系白血病34 项研究
- 心力衰竭31 项研究
- 子宫内膜癌28 项研究
- 抑郁症26 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。